A detailed history of Walleye Capital LLC transactions in Biogen Inc. stock. As of the latest transaction made, Walleye Capital LLC holds 18,700 shares of BIIB stock, worth $3.25 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
18,700
Previous 65,800 71.58%
Holding current value
$3.25 Million
Previous $14.2 Million 69.45%
% of portfolio
0.01%
Previous 0.03%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$190.52 - $236.72 $7.18 Million - $8.93 Million
37,711 Added 393.48%
47,295 $11 Million
Q1 2024

May 15, 2024

BUY
$212.02 - $267.71 $2.03 Million - $2.57 Million
9,584 New
9,584 $2.07 Million
Q3 2023

Nov 14, 2023

SELL
$253.3 - $285.89 $3.36 Million - $3.79 Million
-13,250 Reduced 90.21%
1,438 $369,000
Q2 2023

Aug 14, 2023

BUY
$275.25 - $318.06 $273,598 - $316,151
994 Added 7.26%
14,688 $4.18 Million
Q1 2023

May 15, 2023

SELL
$256.56 - $292.34 $5.34 Million - $6.08 Million
-20,803 Reduced 60.3%
13,694 $3.81 Million
Q4 2022

Feb 14, 2023

BUY
$252.44 - $306.72 $8.71 Million - $10.6 Million
34,497 New
34,497 $9.55 Million
Q2 2022

Aug 08, 2022

SELL
$187.54 - $223.02 $316,004 - $375,788
-1,685 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$193.77 - $244.14 $326,502 - $411,375
1,685 New
1,685 $355,000
Q2 2020

Aug 14, 2020

SELL
$258.66 - $342.55 $46,558 - $61,659
-180 Closed
0 $0
Q1 2020

May 15, 2020

SELL
$268.85 - $341.04 $8,065 - $10,231
-30 Reduced 14.29%
180 $57,000
Q4 2019

Feb 14, 2020

SELL
$220.06 - $304.07 $735,440 - $1.02 Million
-3,342 Reduced 94.09%
210 $62,000
Q3 2019

Nov 14, 2019

BUY
$217.44 - $243.88 $737,556 - $827,240
3,392 Added 2120.0%
3,552 $827,000
Q2 2019

Aug 14, 2019

SELL
$219.29 - $241.72 $313,803 - $345,901
-1,431 Reduced 89.94%
160 $37,000
Q3 2018

Nov 14, 2018

BUY
$293.51 - $383.83 $466,974 - $610,673
1,591 New
1,591 $562,000

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $25B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Walleye Capital LLC Portfolio

Follow Walleye Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Capital LLC with notifications on news.